[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
The Cutting Edge
January 2001

Imiquimod and 5% Fluorouracil Therapy for Anal and Perianal SquamousCell Carcinoma In Situ in an HIV-1–Positive Man

Author Affiliations
 

GEORGE J.HRUZAMDDEEANNAGLASERMDELAINESIEGFRIEDMD

Arch Dermatol. 2001;137(1):14-16. doi:10.1001/archderm.137.1.14
REPORT OF A CASE

A 59-year-old human immunodeficiency virus-1–positive (HIV-1+)white man presented with a nonhealing area that extended extensively aroundthe perianal skin and up into the anal canal. The area had been present forgreater than 2 years with an increase in size over the past 6 months. Biopsieswere performed, and multiple biopsy specimens sampled from the cutaneous surfaceas well as within the distal anal canal showed squamous cell carcinoma insitu.

The patient's HIV-1 disease had been diagnosed approximately 15 yearsearlier, and had been well controlled during most of that time with antiviraltherapy, including protease inhibitors over the past 4 years. The patient'sCD4 cell count was more than 500/µL, and he had an unmeasurable viralload; he had been taking stavudine (40 mg twice daily), lamivudine (150 mgtwice daily), indinavir (400 mg twice daily), and nelfinavir (250 mg 3 timesper day) for approximately 1 year. Other significant medical history included5 basal cell carcinomas, both nodular and superficial types, dating from 1990,with the last tumor treated in 1996.

Physical examination revealed an area of perianal erythema with extensiveareas of ulceration around the rectum and extending into the rectum (Figure 1). Anoscopic examination showed thatthe area of visually atypical anal mucosa extended just inside the anal canal.

Figure 1.
Perianal carcinoma in situ/Bowendisease prior to therapy with 5% fluorouracil and imiquimod therapy.

Perianal carcinoma in situ/Bowendisease prior to therapy with 5% fluorouracil and imiquimod therapy.

Multiple biopsies were performed on the involved skin, including themucosa, to better define the extent of disease.

THERAPEUTIC CHALLENGE

Both radiotherapy and Mohs micrographic surgery for the area of cutaneousinvolvement followed by surgical excision of the rectum were considered aspossible therapies. However, because the patient's HIV-1 disease was wellcontrolled, he wished to try a less aggressive treatment.

SOLUTION

After we confirmed that the results of viral studies for the herpessimplex virus and bacterial and fungal cultures for pathogens were negative,treatment was started with 5% imiquimod cream on a Monday-Wednesday-Fridayschedule. The patient applied the cream at bedtime to the external area ofinvolvement and within the anal canal, washing it off in the morning. Thepatient also applied daily 5% fluorouracil in the morning to the area of cutaneousinvolvement and within the anal canal. Although initially the patient experiencedsome increased irritation, he tolerated the treatment well and continued thetherapy for 16 weeks. Clinically and symptomatically, there was gradual improvementafter approximately 4 weeks of therapy, and at 16 weeks, there was minimalsuperficial ulceration with moderate residual erythema. At approximately 12weeks, the patient showed signs of infection, with increased greenish mucoidmaterial overlying the area of involvement. Cultures showed a mixed bacterialinfection. The patient was treated with 2% topical mupirocin ointment, 0.75%metronidazole cream, and oral levofloxacin, 500 mg, for 10 days with clearingof the infection.

The erythema and residual superficial erosions healed rapidly afterall therapy was discontinued. Approximately 3 weeks later, a biopsy was againperformed on the patient, with specimens taken from multiple sites withinthe prior area of involvement; 4 of the biopsy specimens came from the areaimmediately around the rectal opening (Figure2). In addition, the patient had a ThinPrep (Cytyc Corp, Boxborough,Mass) cytologic smear performed using both a firm spatula and a brush to samplethe anal mucosa extensively, including the areas well proximal to the areaof involvement previously defined clinically and histologically. Follow-upclinical examinations, cutaneous biopsy specimens, and mucosal cytologic examinationshowed no evidence of residual dysplasia.

Figure 2.
Nuclear expression of positiveimmunohistochemical staining for an in situ DNA probe for human papillomavirus 16 (original magnification ×400).

Nuclear expression of positiveimmunohistochemical staining for an in situ DNA probe for human papillomavirus 16 (original magnification ×400).

The initial biopsy specimens showed multiple areas of full-thicknessepithelial dysplasia within both the overlying skin and far distal anal squamousmucosa. The cells were markedly atypical and pleomorphic, with large, hyperchromaticnuclei, many with prominent red nucleoli. In addition, there were some epithelialgiant cells and numerous mitoses, some atypical, and scattered dyskeratoticcells. In situ DNA probes (Pathgene-Enzo Diagnostics, Syosset, NY) for humanpapilloma virus (HPV) types 6/11, 16, 18, and 31 were performed using standardtechniques described by the manufacturer on the initial biopsy sections aswell as the sections used to determine the extent of the tumor. Results ofthe in situ DNA probe for HPV type 16 were positive in the keratinocytic nucleimost numerous in the areas near the periphery of the tumor (Figure 3), but focally positive throughout the tumor.

Figure 3.
Perianal carcinoma in situ 3 weeksafter completing therapy.

Perianal carcinoma in situ 3 weeksafter completing therapy.

Follow-up cutaneous biopsy specimens showed mild dermal fibrosis witha moderate residual chronic inflammatory infiltrate. Flattening of the reteridge pattern was seen in all biopsy specimens. The overlying epidermis showeda bland epithelium with ordered differentiation. ThinPrep cytologic examinationshowed evidence of HPV, but no significant cytologic dysplasia. Follow-upclinical examination, including anoscopic examination, and ThinPrep cytologicexamination 3 months later showed no evidence of recurrence of carcinoma insitu.

COMMENT

Imiquimod belongs to a family of imidazoquinolines that have potentantiviral and antitumor properties in animal models without any demonstrabledirect antiviral or antiproliferative actions. The immune effects of 1- to5-mg/mL imiquimod appear to be mediated, at least in part, through stimulationof innate immunity. In particular, imiquimod therapy has been associated withrelease of monocyte-macrophage–derived cytokines, such as interferonalfa (IFN-α), tumor necrosis factor α (TNF-α), interleukin1α (IL-1α), IL-6, IL-8, IL-12, and prostaglandin E2(PGE2), resulting in a TH1 dominant response.16

Imiquimod has recently been shown to enhance the functional maturationof Langerhans cells, as well as their migration to regional lymph nodes.6,7 Functional maturation and migrationof Langerhans cells are necessary for antigen presentation in the developmentof adaptive immune responses.6,7In one of these studies, imiquimod was also shown to enhance contact hypersensitivityresponses.6 The ability to enhance cutaneousadaptive responses, as well as innate immunologic responses, may be very importantin imiquimod's antiviral and antitumor effects.

The combined effects of TH1 cytokine switching and increasedantigen presentation may be particularly helpful in patients with underlyingimmune deficits, especially those predisposed to a TH2 cytokineswitching pattern, ie, those with atopic dermatitis and HIV-1 disease.79 Since most effectiveantiviral and antitumor responses are mediated through the endogenous systemthe presentation of tumor or viral antigens to CD8+ T cells bymajor histocompatibility complex class I molecules, this potentiation maystill be effective even in patients in whom immune suppression particularlytargets CD4+ T cells, such as those with HIV-1 disease.8,9

Because of the extent of disease in our patient, we decided to use combinedtherapy with both imiquimod and a chemotherapeutic medication, fluorouracil.Fluorouracil has previously been used in the therapy of carcinoma in situfor patients with Bowen disease.1012Fluorouracil is also the first-line therapy for gastrointestinal carcinomas,and in this context it has been combined with IFN-α, one of the principalcytokines induced by imiquimod, to improve its therapeutic index.1315 Interferons alfa,beta, and gamma all enhance the activity of fluorouracil both in vitro andin vivo.16,17 One mechanism bywhich they do this is through the induction of the enzyme thymidine phosphorylase,thereby enhancing the conversion of fluorouracil to its active metabolite,5-fluorodeoxyuridine monophosphate.16 Thisleads to increased depletion of thymidine triphosphate pools and increasedDNA fragmentation.16,17 Interferontreatments also lead to the abrogation of a fluorouracil-associated increasein the enzyme thymidylate synthase, thus increasing tumor sensitivity to fluorouracil.10 Finally, IFN augments plasma fluorouracil levels.16,17

Our patient illustrates a complication for HIV-1+patients associatedwith prolonged survival when these patients are treated with the new, highlyeffective combined antiretroviral therapies.15,18Infections with multiple oncogenic HPV types are very common among HIV-1+homosexualmen, and show almost a 100% association with anal squamous cell carcinoma.14 Although highly effective combined antiretroviraltherapy, with its improvement in the patient's immune status, has proven effectivein dramatically decreasing some viral infections and/or malignancies, eg,molluscum contagiosum and Kaposi sarcoma, HPV infections and their associatedmalignancies have not responded as favorably.1820

Both cytology and anoscopy have proven useful in predicting the developmentof these intraepithelial neoplasms long before they become as extensive asin our patient. Although this patient's oncogenetic HPV infection may havebecome latent, it was not cured, and neither was his HIV-1 infection. Thus,treatment with imiquimod alone or in combination with topical chemotherapeuticagents such as fluorouracil or antiviral agents such as cidovir may proveeffective in controlling epithelial dysplasia and/or squamous cell carcinomain this growing patient population but probably will not result in a permanentcure.15,18

Back to top
Article Information

Accepted for publication August 31, 2000.

The opinions or assertions contained herein are the private views ofthe authors and are not to be construed as official or as reflecting the viewsof the Department of the Army, the Department of the Navy, or the Departmentof Defense.

Corresponding author and reprints: COL Kathleen J. Smith, MC, USA,Department of Dermatology and Pathology, National Naval Medical Center, Bethesda,MD 20889-5600 (e-mail: HSkelIII@aol.com).

References
1.
Imbertson  LMBeaurline  JMCouture  AM  et al.  Cytokine induction in hairless mouse and rat skin after topical applicationof the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998;110734- 739Article
2.
Wagner  TLHorton  VLCarlson  GL  et al.  Induction of cytokines in cynomolgus monkeys by the immune responsemodifiers, imiquimod, S-27609 and S-28463. Cytokine. 1997;9837- 845Article
3.
Tomai  MABirmachu  WCase  MTAly  RedBeutner  KRedMaibach  Hed  et al.  Imiquimod: in vivo and in vitro characteristics and toxicology. CutaneousInfection and Therapy. New York NY: Marcel Dekker Inc1997;405- 415
4.
Testerman  TLGerster  JFImbertson  LM  et al.  Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol. 1995;58365- 372
5.
Wagner  TLAhonen  CLCouture  AM  et al.  Modulation of TH1 and TH2 cytokine production with the immune responsemodifiers, R-848 and imiquimod. Cell Immunol. 1999;19110- 19Article
6.
Suzuki  HWang  BShivji  GM  et al.  Imiquimod, a topical immune response modifier, induces migration ofLangerhans cells. J Invest Dermatol. 2000;114135- 141Article
7.
Burns Jr  RPFerbel  BTomai  MMiller  RGaspari  AA The imidazoquinolines, imiquimod and R-848, induce functional, butnot phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol. 2000;9413- 23Article
8.
Miller  RLGerster  JFOwens  MLSlade  HBTomai  MA Imiquimod applied topically: a novel immune response modifier and newclass of drug [review]. Int J Immunopharmacol. 1999;211- 14Article
9.
Beutner  KRGeisse  JKHelman  DFox  TLGinkel  AOwens  ML Therapeutic response of basal cell carcinoma to the immune responsemodifier imiquimod 5% cream. J Am Acad Dermatol. 1999;411002- 1007Article
10.
Gilson  RJShupack  JLFriedman-Kien  AE  et al. for the Imiquimod Study Group, A randomized, controlled, safety study using imiquimod for the topicaltreatment of anogenital warts in HIV-infected patients. AIDS. 1999;132397- 2404Article
11.
Sturm  HM Bowen's disease and 5-fluorouracil. J Am Acad Dermatol. 1979;1513- 522Article
12.
Bell  HKRhodes  LE Bowen's disease: a retrospective review of clinical management [letter]. Clin Exp Dermatol. 1999;24338- 339Article
13.
Presant  CAWolf  WWaluch  VWiseman  CLWeiz  IShani  J Enhancement of fluorouracil uptake in human colorectal and gastriccancers by interferon or by high-dose methotrexate: an in vivo human studyusing noninvasive (19)F-magnetic resonance spectroscopy. J Clin Oncol. 2000;18255- 261
14.
Bekradda  MCvitkovic  E New possibilities in chemotherapy for colorectal cancer [review]. Ann Oncol. 1999;10105- 111Article
15.
Lacey  HBWilson  GETilston  P  et al.  A study of anal intraepithelial neoplasia in HIV positive homosexualmen. Sex Transm Infect. 1999;75172- 177Article
16.
Makower  DWadler  S Interferons as biomodulators of fluoropyrimidines in the treatmentof colorectal cancer [review]. Semin Oncol. 1999;26663- 671
17.
Schmoll  HJBuchele  TGrothey  ADempke  W Where do we stand with 5-fluorouracil [review]? Semin Oncol. 1999;26589- 605
18.
Palefsky  JM Anal squamous intraepithelial lesions: relation to HIV and human papillomavirusinfection [review]. J Acquir Immune Defic Syndr. 1999;21(suppl 1)S42- S48Article
19.
Blattner  WA Human retrovirus: their role in cancer [review]. Proc Assoc Am Physicians. 1999;111563- 572Article
20.
Calista  DBoschini  ALandi  G Resolution of disseminated molluscum contagiosum with highly activeanti-retroviral therapy (HAART) in patients with AIDS. Eur J Dermatol. 1999;9211- 213
×